IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the ...

The hormone replacement and therapeutic wellness market has been a growing concern for many companies, but Biote is seeing ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ -- OBGYN Specialists of Columbus is helping women better ...

IRVING, Texas--(BUSINESS WIRE)-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...

As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT, is ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (BTMD) (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, ...

biote Corp. (NASDAQ:BTMD) Q4 2025 Earnings Call Transcript March 11, 2026 biote Corp. beats earnings expectations. Reported EPS is $0.06339, expectations were $0.04. Operator: Good day, and welcome to ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

Guidance shifted from reiterating 2025 revenues above $190 million and adjusted EBITDA above $50 million to projecting 2026 revenues above $190 million and adjusted EBITDA greater than $38 million, ...

IRVING, Texas, February 25, 2026--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients’ lives by providing hormone ...